These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19574203)

  • 1. mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).
    Vázquez-Martín A; Oliveras-Ferraros C; del Barco S; Martín-Castillo B; Menéndez JA
    Clin Transl Oncol; 2009 Jul; 11(7):455-9. PubMed ID: 19574203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
    Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
    Gayle SS; Arnold SL; O'Regan RM; Nahta R
    Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.
    Frampton JE
    Drugs; 2009 Oct; 69(15):2125-48. PubMed ID: 19791830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
    Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
    Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
    BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
    Jegg AM; Ward TM; Iorns E; Hoe N; Zhou J; Liu X; Singh S; Landgraf R; Pegram MD
    Breast Cancer Res Treat; 2012 Dec; 136(3):683-92. PubMed ID: 23089982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
    Brady SW; Zhang J; Tsai MH; Yu D
    Cancer Biol Ther; 2015; 16(3):402-11. PubMed ID: 25692408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
    Eichhorn PJ; Gili M; Scaltriti M; Serra V; Guzman M; Nijkamp W; Beijersbergen RL; Valero V; Seoane J; Bernards R; Baselga J
    Cancer Res; 2008 Nov; 68(22):9221-30. PubMed ID: 19010894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?
    Ito Y; Tokudome N; Sugihara T; Takahashi S; Hatake K
    Breast Cancer; 2007; 14(2):156-62. PubMed ID: 17485900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.
    Gradishar WJ
    Ann Oncol; 2013 Oct; 24(10):2492-2500. PubMed ID: 23827380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
    Geyer CE; Forster J; Lindquist D; Chan S; Romieu CG; Pienkowski T; Jagiello-Gruszfeld A; Crown J; Chan A; Kaufman B; Skarlos D; Campone M; Davidson N; Berger M; Oliva C; Rubin SD; Stein S; Cameron D
    N Engl J Med; 2006 Dec; 355(26):2733-43. PubMed ID: 17192538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
    Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
    Eur J Cancer; 2016 Mar; 56():85-92. PubMed ID: 26829011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.
    Moody SE; Schinzel AC; Singh S; Izzo F; Strickland MR; Luo L; Thomas SR; Boehm JS; Kim SY; Wang ZC; Hahn WC
    Oncogene; 2015 Apr; 34(16):2061-71. PubMed ID: 24909179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.